Technology supports the use of chia seeds to help improve health and delay signs of aging
News Highlights: Technology supports the use of chia seeds to help improve health and delay signs of aging
IMAGE: An improved extraction method from innovators at Purdue University with chia seeds may provide new options for anti-aging products, nutritional foods, and drug capsules. view more
Credit: Andrea Liceaga / Purdue University
WEST LAFAYETTE, Ind. – An improved chia seed extraction method may provide new options for nutritional foods, drug capsules and anti-aging products.
Recommended
A Purdue University team developed and patented the method to separate mucus from chia seeds, yielding a protein-rich chia seed meal with improved bioactivity and functionality compared to conventional methods.
Purdue University-affiliated startup receives NSF grant to study severe COVID-19 cases
A Purdue University-affiliated startup is receiving national support to pursue a strategy to treat severe COVID-19 cases and possible future outbreaks involving other viruses.
Akanocure Pharmaceuticals Inc. has received a $256,000 Phase I research grant from the National Science Foundation.
NSF is proud to support the technology of the future by thinking beyond incremental developments and funding the most creative, impactful ideas across all markets and areas of science and engineering. With the support of our research funds, any deep technology startup or small business can guide basic science into meaningful solutions that address tremendous needs.
Dr. J. Paul Robinson, the SVM Professor of Cytomics in the College of Veterinary Medicine’s Department of Basic Medical Sciences, is one of six Purdue University researchers receiving a total of nearly $209,000 from the Trask Innovation Fund to help their labs commercialize their innovations. The fund is a development program established to support projects that advance the commercial value of Purdue intellectual property.
Dr. Robinson holds a joint appointment in the College of Veterinary Medicine and the Weldon School of Biomedical Engineering. He is receiving Trask funding for a handheld device for real-time detection of pathogens, toxins, and contaminating chemicals for biodefense and food analysis.
6 Purdue innovators advance their technologies through Trask funding
Six Purdue University researchers have received a total of $208,628 from the Trask Innovation Fund. The fund makes awards twice a year to aid faculty and staff with their patented innovations that are being commercialized through the Purdue Research Foundation Office of Technology Commercialization, which is housed in the Convergence Center in Discovery Park District. (Image provided)
WEST LAFAYETTE, Ind. – Six Purdue University researchers have received a total of $208,628 from the Trask Innovation Fund to help their labs commercialize their innovations.
The fund is a development program established to support projects that advance the commercial value of Purdue intellectual property. The fund makes awards twice a year to aid faculty and staff with their patented innovations that are being commercialized through the Purdue Research FoundationOffice of Technology Commercialization.
Purdue University innovators developed a stabilized form of human calcitonin, which is a peptide drug already used for people with osteoporosis. Researchers at Purdue created a prodrug form of the peptide hormone to increase its effectiveness as an osteoporosis treatment.